journal
MENU ▼
Read by QxMD icon Read
search

Therapeutic Advances in Musculoskeletal Disease

journal
https://www.readbyqxmd.com/read/30210584/the-role-of-golimumab-in-inflammatory-arthritis-a-review-of-the-evidence
#1
REVIEW
Zunera Tahir, Arthur Kavanaugh
Background: Golimumab (GOL) is a tumor necrosis factor inhibitor that is used for various types of inflammatory arthritis such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS). This article is a systematic review of the evidence for the efficacy and safety of golimumab in inflammatory arthritides, specifically RA, PsA and AS. Methods: We conducted a search of randomized controlled trails in MEDLINE [PubMed], CENTRAL, Embase, and Current Controlled Trials databases (ClinicalTrials...
September 2018: Therapeutic Advances in Musculoskeletal Disease
https://www.readbyqxmd.com/read/30210583/the-role-of-secukinumab-in-the-treatment-of-psoriatic-arthritis-and-ankylosing-spondylitis
#2
REVIEW
Leticia Garcia-Montoya, Helena Marzo-Ortega
Psoriatic arthritis and ankylosing spondylitis are chronic inflammatory diseases that can cause significant disability. The commercialization of the first tumour necrosis factor (TNF) inhibitors led to a radical improvement of the quality of life of people affected by these conditions; however, response was not universal, highlighting the need for alternative therapeutic targets. Secukinumab is a monoclonal interleukin (IL)-17A inhibitor which has been proven efficacious for psoriatic arthritis and ankylosing spondylitis in recent clinical trials...
September 2018: Therapeutic Advances in Musculoskeletal Disease
https://www.readbyqxmd.com/read/30181786/inflammation-obesity-and-rheumatic-disease-common-mechanistic-links-a-narrative-review
#3
REVIEW
Elena Nikiphorou, George E Fragoulis
Obesity represents a rising global health concern, linked to significant social, psychological and physical burden to the individual affected, people around them and the society as a whole. Obesity has been described as a low-grade inflammatory condition, associated with increased production of pro-inflammatory mediators like tumor necrosis factor alpha or interleukin 6 and altered expression of adipokines. Adipokines, mainly produced by adipose tissue, have mixed pro- and anti-inflammatory properties. Obesity rarely exists on its own; instead, it tends to coexist with (often multiple) other comorbidities, including metabolic, cardiovascular, and rheumatic and musculoskeletal diseases (RMDs)...
August 2018: Therapeutic Advances in Musculoskeletal Disease
https://www.readbyqxmd.com/read/30023010/hypophosphatemia-in-the-setting-of-metabolic-bone-disease-case-reports-and-diagnostic-algorithm
#4
Alvin Lee Day, Sarah L Morgan, Kenneth G Saag
Osteoporosis is the most commonly encountered metabolic bone disease, and metabolic bone-disease clinics have been established to assist in the diagnosis and treatment of uncommon causes of low bone-mineral density. Hypophosphatemia leading to metabolic bone disease may be encountered, and an understanding of phosphate homeostasis can aid in the diagnosis. Two cases of hypophosphatemia leading to low bone-mineral densities were seen at the University of Alabama at Birmingham Osteoporosis Clinic. We developed a diagnostic algorithm, and the laboratory values of each patient were tested with the algorithm...
July 2018: Therapeutic Advances in Musculoskeletal Disease
https://www.readbyqxmd.com/read/30023009/improving-drug-adherence-in-osteoporosis-an-update-on-more-recent-studies
#5
REVIEW
Ayesha Jaleel, Kenneth G Saag, Maria I Danila
Similar to other chronic diseases such as diabetes and hypertension, osteoporosis has struggled with suboptimal medication adherence, resulting in an increased risk of fractures and all-cause mortality. The goal of this narrative review was to summarize interventions to improve medication adherence in osteoporosis. Because past reviews of this topic covered published literature through 2013, we conducted our literature search to include the period between January 2012 and November 2017. We identified 10 studies evaluating healthcare system and patient interventions aimed at improving osteoporosis treatment adherence, including three fracture liaison service (FLS) programs, one pharmacist-delivered counseling program, and six patient-directed interventions consisting of three coaching or counseling programs and three interventions using reminder prompts...
July 2018: Therapeutic Advances in Musculoskeletal Disease
https://www.readbyqxmd.com/read/29942364/ankylosing-spondylitis-and-axial-spondyloarthritis-recent-insights-and-impact-of-new-classification-criteria
#6
REVIEW
Fabian Proft, Denis Poddubnyy
Development of the Assessment in Spondyloarthritis International Society (ASAS) classification criteria for axial spondyloarthritis (SpA) was one of the major breakthroughs in the field over the past decade. Despite some concerns related to the specificity of the criteria, they stimulated research into the early stage of the disease. This resulted in major advances in the understanding of the course of the disease, revealing predictors of progression, improvement in early diagnosis and treatment in axial SpA...
June 2018: Therapeutic Advances in Musculoskeletal Disease
https://www.readbyqxmd.com/read/29942363/the-role-of-the-jak-stat-signal-pathway-in-rheumatoid-arthritis
#7
REVIEW
Charles J Malemud
Proinflammatory cytokine activation of the Janus kinase/signal transducers and activators of transcription (JAK/STAT) signal transduction pathway is a critical event in the pathogenesis and progression of rheumatoid arthritis. Under normal conditions, JAK/STAT signaling reflects the influence of negative regulators of JAK/STAT, exemplified by the suppressor of cytokine signaling and protein inhibitor of activated STAT. However, in rheumatoid arthritis (RA) both of these regulators are dysfunctional. Thus, continuous activation of JAK/STAT signaling in RA synovial joints results in the elevated level of matrix metalloproteinase gene expression, increased frequency of apoptotic chondrocytes and most prominently 'apoptosis resistance' in the inflamed synovial tissue...
June 2018: Therapeutic Advances in Musculoskeletal Disease
https://www.readbyqxmd.com/read/29942362/the-clinical-potential-of-romosozumab-for-the-prevention-of-fractures-in-postmenopausal-women-with-osteoporosis
#8
REVIEW
Anne Sophie Koldkjær Sølling, Torben Harsløf, Bente Langdahl
The glycoprotein sclerostin inhibits activation of the canonical Wnt pathway and thereby suppresses bone formation by inhibiting the osteoblasts. Additionally, sclerostin increases bone resorption by stimulating the production of receptor activator of nuclear factor kappa-β-ligand (RANKL). Romosozumab (ROMO) is a monoclonal antibody against sclerostin. Phase III clinical trials in postmenopausal women with osteoporosis have shown that ROMO increases bone mineral density at the lumbar spine and hip and reduces the risk of vertebral and clinical fractures in comparison with placebo...
June 2018: Therapeutic Advances in Musculoskeletal Disease
https://www.readbyqxmd.com/read/29619094/foot-osteoarthritis-latest-evidence-and-developments
#9
REVIEW
Edward Roddy, Hylton B Menz
Foot osteoarthritis (OA) is a common problem in older adults yet is under-researched compared to knee or hand OA. Most existing studies focus on the first metatarsophalangeal joint, with evidence relating to midfoot OA being particularly sparse. Symptomatic radiographic foot OA affects 17% of adults aged 50 years and over. The first metatarsophalangeal joint is most commonly affected, followed by the second cuneometatarsal and talonavicular joints. Epidemiological studies suggest the existence of distinct first metatarsophalangeal joint and polyarticular phenotypes, which have differing clinical and risk factor profiles...
April 2018: Therapeutic Advances in Musculoskeletal Disease
https://www.readbyqxmd.com/read/29619093/aromatase-inhibitors-are-associated-with-a-higher-fracture-risk-than-tamoxifen-a-systematic-review-and-meta-analysis
#10
REVIEW
Olivia L Tseng, John J Spinelli, Carolyn C Gotay, Wan Y Ho, Mary L McBride, Martin G Dawes
Background: In this paper, our aim was to systematically evaluate published evidence of bone fracture risk associated with tamoxifen and aromatase inhibitors in women aged 65 and under, and diagnosed with nonmetastatic breast cancer. Methods: We comprehensively searched MEDLINE, EMBASE and CINAHL databases from January 1997 through May 2015, and reference lists of the selected articles to identify English-language randomized controlled trials and cohort studies of fracture risk...
April 2018: Therapeutic Advances in Musculoskeletal Disease
https://www.readbyqxmd.com/read/29492111/efficacy-and-safety-of-sarilumab-in-patients-with-active-rheumatoid-arthritis
#11
REVIEW
Delilah McCarty, April Robinson
The mainstay of rheumatoid arthritis (RA) treatment involves the use of medications that slow disease progression and reduce inflammation. Inadequate treatment responses and intolerances to conventional RA treatment have led to the development of biologic agents for the management of moderate-to-severe disease activity. Interleukin-6 (IL-6) inhibition is one of the targets for biologic activity in RA treatment. IL-6 is found in excess in the synovial fluid and contributes to joint erosion through its action on osteoclast cells...
March 2018: Therapeutic Advances in Musculoskeletal Disease
https://www.readbyqxmd.com/read/29387178/intra-articular-hyaluronan-injections-for-the-treatment-of-osteoarthritis-perspective-for-the-mechanism-of-action
#12
Nicolas S Piuzzi, Ronald J Midura, George F Muschler, Vincent C Hascall
No abstract text is available yet for this article.
February 2018: Therapeutic Advances in Musculoskeletal Disease
https://www.readbyqxmd.com/read/29387177/management-of-primary-sj%C3%A3-gren-s-syndrome-recent-developments-and-new-classification-criteria
#13
REVIEW
Nicoletta Del Papa, Claudio Vitali
For many years primary Sjögren's syndrome (pSS) has been considered an orphan disease, since no specific therapies were recognized as being capable of contrasting the development and progression of this disorder. The treatment of oral and ocular features, as well as of the systemic organ involvement, has been entrusted to the joint management of different subspecialty physicians, like ophthalmologists, otolaryngologists, dentists and rheumatologists. These latter subspecialty doctors are usually more involved in the treatment of systemic extraglandular involvement and, to do it, they have long been using the conventional therapies borrowed by the treatment schedules adopted in other systemic autoimmune diseases...
February 2018: Therapeutic Advances in Musculoskeletal Disease
https://www.readbyqxmd.com/read/29387176/investigational-therapies-targeting-the-granulocyte-macrophage-colony-stimulating-factor-receptor-%C3%AE-in-rheumatoid-arthritis-focus-on-mavrilimumab
#14
REVIEW
Andrew D Cook, John A Hamilton
Mavrilimumab (formerly CAM-3001) is a high-affinity, immunoglobulin G4 monoclonal antibody (mAb) against the granulocyte macrophage colony-stimulating factor (GM-CSF) receptor-α chain. Phase I and II trials in patients with rheumatoid arthritis (RA) treated with mavrilimumab have shown encouraging results with respect to both safety and efficacy. No significant adverse events have so far been noted. The trials have demonstrated significant clinical benefit, meeting primary endpoints. Furthermore, for RA patients treated with mavrilimumab, who were tumour necrosis factor (TNF) inhibitor-inadequate responders, there are encouraging preliminary data indicating benefit and identifying potential biomarkers predictive of patients likely to find benefit...
February 2018: Therapeutic Advances in Musculoskeletal Disease
https://www.readbyqxmd.com/read/29290763/a-narrative-review-on-the-difficulties-associated-with-fibromyalgia-diagnosis
#15
REVIEW
Dinesh Kumbhare, Sara Ahmed, Scott Watter
Fibromyalgia presents a clinical enigma as its pathophysiology is not well understood and its symptoms are nonspecific and overlap with many disorders, making its diagnosis a challenge for clinicians and researchers. Efforts have been made to develop a set of diagnostic criteria for this disorder. However, these criteria rely heavily on expert clinician opinion and produce a large heterogeneity within the diagnosed population. With no present specific technique reflecting the underlying pathophysiology of fibromyalgia, a definitive diagnosis of fibromyalgia remains elusive...
January 2018: Therapeutic Advances in Musculoskeletal Disease
https://www.readbyqxmd.com/read/29290762/an-autumn-tale-geriatric-rheumatoid-arthritis
#16
REVIEW
Senol Kobak, Cemal Bes
Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by erosive arthritis and systemic organ involvement. The disease may affect all ages and both sexes; usually it is seen in young women aged 25-45. Recent studies have shown that RA is among the most common inflammatory disease in older age groups. While elderly-onset rheumatoid arthritis (EORA) is still discussed in the literature, it is generally accepted as a disease beginning after 65 years of age. Compared with young-onset rheumatoid arthritis (YORA), it was found that EORA had different characteristics...
January 2018: Therapeutic Advances in Musculoskeletal Disease
https://www.readbyqxmd.com/read/29201156/evidence-based-management-of-raynaud-s-phenomenon
#17
REVIEW
Ariane L Herrick
Raynaud's phenomenon (RP) is relevant to the rheumatologist because it may signify an underlying connective tissue disease and also because it can be very challenging to treat, especially when it has progressed to digital ulceration or critical ischaemia. This review article discusses diagnosis (does this patient have an underlying connective tissue disease?), including the role for nailfold capillaroscopy, and treatment. Management of 'uncomplicated' RP is first described and then treatment of RP complicated by progression to digital ulceration or critical ischaemia, highlighting recent advances (including phosphodiesterase type 5 inhibition, and endothelin 1 receptor antagonism) and the evidence base underpinning these...
December 2017: Therapeutic Advances in Musculoskeletal Disease
https://www.readbyqxmd.com/read/29201155/critical-issues-and-current-challenges-in-osteoporosis-and-fracture-prevention-an-overview-of-unmet-needs
#18
REVIEW
Willem F Lems, Hennie G Raterman
Osteoporosis is a silent disease with increasing prevalence due to the global ageing population. Decreased bone strength and bone quality is the hallmark of osteoporosis which leads to an increased risk of fragility fractures in elderly. It has been estimated that approximately ~50% of women will suffer during their lifetime from an osteoporotic fracture. This must be considered as a major health concern, as it has previously been established that fragility fracture has been associated with decreased quality of life due to increased disability, more frequent hospital admission and most importantly, osteoporotic fractures have been related to an augmented mortality risk...
December 2017: Therapeutic Advances in Musculoskeletal Disease
https://www.readbyqxmd.com/read/29344111/corrigendum
#19
(no author information available yet)
[This corrects the article DOI: 10.1177/1759720X17729641.].
November 2017: Therapeutic Advances in Musculoskeletal Disease
https://www.readbyqxmd.com/read/29344110/anti-interleukin-and-interleukin-therapies-for-psoriasis-current-evidence-and-clinical-usefulness
#20
REVIEW
Ya-Chu Tsai, Tsen-Fang Tsai
Anti-interleukin (IL) therapies have emerged as a major treatment for patients with moderate-to-severe psoriasis. This article reviews the up-to-date results of pivotal clinical trials targeting the interleukins used for the treatment of psoriasis, including IL-1, IL-2, IL-6, IL-8, IL-10, IL-12, IL-17, IL-20, IL-22, IL-23, IL-36 and bispecific biologics IL-17A/tumor necrosis factor alpha (TNF-α). Cytokines involved in the circuits of psoriasis inflammation without ongoing clinical trials are also mentioned (IL-9, IL-13, IL-15, IL-16, IL-18, IL-19, IL-21, IL-24, IL-27, IL-33, IL-35, IL-37, and IL-38)...
November 2017: Therapeutic Advances in Musculoskeletal Disease
journal
journal
42615
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"